These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36970848)

  • 1. Transthyretin Amyloid Cardiomyopathy Risk Evaluation in a Cohort of Patients With Heart Failure.
    Suh AA; Shaw PB; Jeong MY; Olson KL; Delate T
    Perm J; 2023 Jun; 27(2):51-60. PubMed ID: 36970848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records.
    Moya A; Oeste CL; Beles M; Verstreken S; Dierckx R; Heggermont W; Bartunek J; Bogaerts E; Masuy I; Hens D; Bertolone D; Vanderheyden M
    ESC Heart Fail; 2023 Dec; 10(6):3483-3492. PubMed ID: 37726928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy.
    Lauppe R; Liseth Hansen J; Fornwall A; Johansson K; Rozenbaum MH; Strand AM; Vakevainen M; Kuusisto J; Gude E; Smith JG; Gustafsson F
    ESC Heart Fail; 2022 Jun; 9(3):1636-1642. PubMed ID: 35365974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
    JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries.
    Lauppe R; Liseth Hansen J; Fornwall A; Johansson K; Rozenbaum MH; Strand AM; Väkeväinen M; Kuusisto J; Gude E; Smith JG; Gustafsson F
    ESC Heart Fail; 2022 Aug; 9(4):2528-2537. PubMed ID: 35560802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden.
    Lauppe RE; Liseth Hansen J; Gerdesköld C; Rozenbaum MH; Strand AM; Vakevainen M; Kuusisto J; Gude E; Gustafsson F; Smith JG
    Open Heart; 2021 Oct; 8(2):. PubMed ID: 34645699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
    Davies DR; Redfield MM; Scott CG; Minamisawa M; Grogan M; Dispenzieri A; Chareonthaitawee P; Shah AM; Shah SJ; Wehbe RM; Solomon SD; Reddy YNV; Borlaug BA; AbouEzzeddine OF
    JAMA Cardiol; 2022 Oct; 7(10):1036-1044. PubMed ID: 36069809
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Tahara N; Lairez O; Endo J; Okada A; Ueda M; Ishii T; Kitano Y; Lee HE; Russo E; Kubo T
    ESC Heart Fail; 2022 Feb; 9(1):251-262. PubMed ID: 34841715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of transthyretin amyloid cardiomyopathy in patients admitted for acute heart failure.
    Spaccavento A; Rodríguez MDR; Meretta A; Elissamburu P; Carvelli V; Gobbo M; Rosa D; Masoli O; Conde D; Costabel JP
    Curr Probl Cardiol; 2024 Mar; 49(3):102385. PubMed ID: 38184135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Madhani A; Sabogal N; Massillon D; Paul LD; Rodriguez C; Fine D; Helmke S; Winburn M; Kurian D; Raiszadeh F; Teruya S; Cohn E; Einstein AJ; Miller EJ; Connors LH; Maurer MS; Ruberg FL
    J Am Heart Assoc; 2023 Aug; 12(15):e028973. PubMed ID: 37486082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
    Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and health care resource use of patients at risk for wild-type transthyretin amyloid cardiomyopathy identified by machine learning model.
    Bruno M; Sheer R; Reed C; Schepart A; Nair R; Simmons JD
    J Manag Care Spec Pharm; 2023 May; 29(5):530-540. PubMed ID: 37121249
    [No Abstract]   [Full Text] [Related]  

  • 13. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
    Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
    Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
    Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
    Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
    Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?
    Aus dem Siepen F; Hein S; Prestel S; Baumgärtner C; Schönland S; Hegenbart U; Röcken C; Katus HA; Kristen AV
    Clin Res Cardiol; 2019 Dec; 108(12):1324-1330. PubMed ID: 30953182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transthyretin amyloid cardiomyopathy].
    Czepluch F
    Inn Med (Heidelb); 2023 Sep; 64(9):823-829. PubMed ID: 37540258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Rationale the SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study.
    Ruberg FL; Blaner WS; Chiuzan C; Connors LH; Einstein AJ; Fine D; Helmke S; Kurian D; Pandey S; Raiszadeh F; Rodriguez C; Sabogal N; Teruya S; Winburn M; Chung WK; Cohn E; Miller EJ; Kelly JW; Maurer MS
    J Am Heart Assoc; 2023 Apr; 12(8):e028534. PubMed ID: 37066788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Pitfall and Clinical Characteristics of Variant Versus Wild-Type Transthyretin Amyloid Cardiomyopathy in Asian Population: The Korean Nationwide Cohort Study.
    Kim D; Youn JC; Lee HW; Oh J; Son JW; Cho HJ; Lee S; Shah NR; Kittleson MM; Jeon ES
    J Korean Med Sci; 2024 May; 39(19):e163. PubMed ID: 38769922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
    Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
    JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.